[Use of the Gepon immunomodulator for ulcerative colitis treatment].
Malakhova NS, Pichugin AV, Khalif IL, Ataullakhanov RI · 2005 · Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · PMID 15991847
What does this source report?
The report describes clinical and endoscopic improvement in 83.3% of the treated patients.
- Population and setting
- 36 patients with resistant distal ulcerative colitis
- Evidence type
- Uncontrolled human report
- Preparation
- See the original report; formulation details require verification.
- Source language
- English indexed abstract; original language:
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- No concurrent comparator is described; the reported response proportion is not an effect versus placebo or standard care.
- Full methods, reporting completeness and independent replication remain to be appraised.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Abstract reviewed
Source access and review scope
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Recorded source-check date: 2026-10-05. This date does not imply a completed systematic review.
Source provenance: Original journal report
Cite and trace this record
Original source: Malakhova NS, Pichugin AV, Khalif IL, Ataullakhanov RI. [Use of the Gepon immunomodulator for ulcerative colitis treatment]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · PMID 15991847 2005.
Molekul research summary: https://molekul.io/research/audit-15991847. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry